Eli Lilly and Company $LLY Holdings Lifted by Omnia Family Wealth LLC

Omnia Family Wealth LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,405 shares of the company’s stock after purchasing an additional 144 shares during the period. Eli Lilly and Company makes up approximately 0.7% of Omnia Family Wealth LLC’s holdings, making the stock its 21st biggest position. Omnia Family Wealth LLC’s holdings in Eli Lilly and Company were worth $1,875,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the 1st quarter worth about $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the 1st quarter worth about $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 1.7%

LLY stock opened at $826.20 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The firm has a market cap of $781.97 billion, a PE ratio of 54.00, a P/E/G ratio of 1.16 and a beta of 0.47. The firm has a 50 day simple moving average of $745.96 and a 200 day simple moving average of $766.28. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business earned $3.92 earnings per share. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Guggenheim upped their price target on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.